Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03007225 Completed - Clinical trials for HepatoCellular Carcinoma

Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients

Start date: July 2015
Phase: Phase 4
Study type: Interventional

This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization

NCT ID: NCT03007212 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis

Start date: September 2014
Phase: Phase 4
Study type: Interventional

Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.

NCT ID: NCT03006926 Completed - Clinical trials for Hepatocellular Carcinoma

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Start date: February 13, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).

NCT ID: NCT02995096 Completed - Clinical trials for Liver Transplantation

Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

Start date: January 2016
Phase:
Study type: Observational [Patient Registry]

Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.

NCT ID: NCT02990351 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt

Start date: December 2014
Phase: N/A
Study type: Observational

This study aimed to analyze the outcomes of loco-regional treatment prior Living Donor Liver Transplantation in patients with HCC.

NCT ID: NCT02989922 Completed - Clinical trials for Hepatocellular Carcinoma Non-Resectable

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Start date: November 15, 2016
Phase: Phase 2
Study type: Interventional

This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and Overall Survival when compare with SOC.

NCT ID: NCT02988440 Completed - Clinical trials for Hepatocellular Carcinoma

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Start date: April 20, 2017
Phase: Phase 1
Study type: Interventional

A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line. There will be a dose escalation part and a dose expansion part.

NCT ID: NCT02981498 Completed - Clinical trials for Hepatocellular Carcinoma

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Start date: June 2015
Phase: Phase 2
Study type: Interventional

To evaluate safety and efficacy of combined hepatic arterial infusion (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT02973685 Completed - Clinical trials for HepatoCellular Carcinoma

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Start date: October 1, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC A/B.

NCT ID: NCT02973516 Completed - Clinical trials for HepatoCellular Carcinoma

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This study is an exploratory study aiming to collect data about diagnosis efficacy (sensitivity and specificity) of P03277 triphasic liver imaging for HCC in subjects with suspected small nodules and chronic liver disease. 30 subjects will be included, having HCC confirmed or not by previous enhanced CT and/or MRI and before any biopsy for histology analysis. The standard of reference for diagnosis will be given by the site according to their standard of care and adapted from EASL/EORTC diagnostic criteria (considering previous contrast enhanced imaging (CT and/or MRI) and/or biopsy specimen analysis given on-site and/or the more recent AFP results available). 10 additional subjects will be included to explore the diagnostic efficacy for HCC at half dose of P03277.